GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » ROA %

Vor Biopharma (Vor Biopharma) ROA % : -49.88% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vor Biopharma's annualized Net Income for the quarter that ended in Dec. 2023 was $-105.04 Mil. Vor Biopharma's average Total Assets over the quarter that ended in Dec. 2023 was $210.57 Mil. Therefore, Vor Biopharma's annualized ROA % for the quarter that ended in Dec. 2023 was -49.88%.

The historical rank and industry rank for Vor Biopharma's ROA % or its related term are showing as below:

VOR' s ROA % Range Over the Past 10 Years
Min: -412.31   Med: -74.24   Max: -33.99
Current: -47.18

During the past 6 years, Vor Biopharma's highest ROA % was -33.99%. The lowest was -412.31%. And the median was -74.24%.

VOR's ROA % is ranked worse than
59.38% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs VOR: -47.18

Vor Biopharma ROA % Historical Data

The historical data trend for Vor Biopharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vor Biopharma ROA % Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -200.11 -101.10 -43.26 -33.99 -47.38

Vor Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.82 -39.43 -45.38 -56.02 -49.88

Competitive Comparison of Vor Biopharma's ROA %

For the Biotechnology subindustry, Vor Biopharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vor Biopharma's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's ROA % distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's ROA % falls into.



Vor Biopharma ROA % Calculation

Vor Biopharma's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-117.863/( (299.366+198.126)/ 2 )
=-117.863/248.746
=-47.38 %

Vor Biopharma's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-105.044/( (223.023+198.126)/ 2 )
=-105.044/210.5745
=-49.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Vor Biopharma  (NAS:VOR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-105.044/210.5745
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-105.044 / 0)*(0 / 210.5745)
=Net Margin %*Asset Turnover
=N/A %*0
=-49.88 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Vor Biopharma ROA % Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vor Biopharma (Vor Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Executives
Eyal C. Attar officer: Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen officer: Chief Financial Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak officer: Chief Medical Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim officer: Chief Technology Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty officer: Chief Scientific Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang director, officer: President and CEO C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107

Vor Biopharma (Vor Biopharma) Headlines